-
News
- Technology /AI
- Medical journals
- Topics
News
Polatuzumab Vedotin in Combination Treatment of Patients with R/R DLBCL
3. 2. 2020 Source: Non-Hodgkin Lymphomas and CLLPolatuzumab Vedotin is a conjugate of a cytostatic agent and an antibody against CD79b, a component of the B-lymphocyte receptor typically expressed by diffuse large B-cell lymphoma (DLBCL) cells. In combination with bendamustine and rituximab (pola-BR), this drug is administered in the 3rd and subsequent lines of treatment for relapsed or refractory (R/R) DLBCL. If allogeneic hematopoietic stem cell transplantation (HSCT) is not feasible, patients with R/R DLBCL generally have a very poor prognosis, with limited further treatment options.…
End of Unnecessary Biopsies? Prostate Health Index (PHI) in Detecting Aggressive Carcinoma
The Prostate Health Index (PHI) combines the results of three blood-derived parameters: total PSA (tPSA), free PSA (fPSA), and [-2]proPSA (p2PSA) into a single numerical score: PHI = (p2PSA / fPSA ×…2. 2. 2020 Source: Prostate Health Index
Prediction of Cancer Aggressiveness: Prostate Health Index (PHI) as a Promising Future Marker
The Prostate Health Index (PHI) is a diagnostic blood test that combines the levels of prostate-specific antigen (PSA), free PSA (fPSA), and the isoform [-2]proPSA (p2PSA). Its use in prostate cancer…2. 2. 2020 Source: Prostate Health Index
Cardiovascular Benefit of SGLT2 Inhibitors Confirmed
The cardiovascular (CV) benefit of SGLT2 inhibitors in type 2 diabetics, demonstrated by empagliflozin in the EMPA-REG OUTCOME study, has also been confirmed by studies with canagliflozin (CANVAS), a...31. 1. 2020 Source: Diabetes
Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?
Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less…31. 1. 2020 Source: Cardiovascular Risks
Efficacy and Safety of High Doses of Enoxaparin in Preventing Thromboembolic Disease in Morbidly Obese Patients
Thromboembolic disease is a significant cause of morbidity and mortality in hospitalized patients, with morbid obesity being a notable risk factor for thromboembolism. Various thromboprophylaxis…28. 1. 2020 Source: Thromboprophylaxis
Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often…28. 1. 2020 Source: Thromboprophylaxis
Evaluation of the m7-FLIPI score in patients with follicular lymphoma revealed a promising predictive biomarker for determining suitable chemotherapy
The authors of a study presented at the December congress of the American Society of Hematology (ASH) in Orlando introduced a new prognostic tool, m7-FLIPI, for determining the risk level of patients…27. 1. 2020 Source: Non-Hodgkin Lymphomas and CLL
Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
In December, the European Commission approved the expansion of the indication for Roche's medicinal product Kadcyla, which contains the active substance trastuzumab emtansine. This expansion makes…23. 1. 2020 Source: Breast Carcinoma
Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist − NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of…20. 1. 2020 Source: Antiemetic Therapy
Cost Effectiveness of Netupitant/Palonosetron Combination in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting
A recently published study compared the costs of achieving a complete response to antiemetic therapy in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) when using a combination of…20. 1. 2020 Source: Antiemetic Therapy
Impact of Oral Antidiabetics on Heart Failure
Diabetes mellitus is primarily perceived as a risk factor for ischemic heart disease and general atherosclerotic complications. However, an equally significant problem is the association between diabetes...19. 1. 2020 Source: Diabetes
Position of Levodropropizine in Cough Therapy
An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using…15. 1. 2020 Source: Cough Therapy
Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and…15. 1. 2020 Source: Hemophilia
The World of Viruses is Constantly Evolving and Bringing Us New Surprises
The last decade has been marked by the emergence of new, as well as re-emerging human pathogens responsible for various infectious diseases. Viruses, especially those of zoonotic origin that originate...13. 1. 2020 Source: Anti-Infectives
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Technology /AI